RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share
NEW YORK, Jan 20, 2026, 18:51 EST — After-hours Rapt Therapeutics (NASDAQ: RAPT) surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech. GSK’s $58-a-share cash bid values the deal at about a 65% premium over Monday’s close. This is the first big move by CEO Luke Miels, who just took…